On Tuesday, Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) opened higher 0.54% from the last session, before settling in for the closing price of $471.25. Price fluctuations for VRTX have ranged from $335.82 to $486.42 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 27.16%. Company’s average yearly earnings per share was noted 10.93% at the time writing. With a float of $257.37 million, this company’s outstanding shares have now reached $257.70 million.
Let’s determine the extent of company efficiency that accounts for 5400 employees.
Vertex Pharmaceuticals, Inc. (VRTX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Vertex Pharmaceuticals, Inc. is 0.26%, while institutional ownership is 92.80%. The most recent insider transaction that took place on Jun 26 ’24, was worth 1,075,522. In this transaction EVP and CMO of this company sold 2,280 shares at a rate of $471.72, taking the stock ownership to the 30,099 shares. Before that another transaction happened on Jun 12 ’24, when Company’s EVP, Chief Technical Ops. Off. sold 7,288 for $478.00, making the entire transaction worth $3,483,664. This insider now owns 15,972 shares in total.
Vertex Pharmaceuticals, Inc. (VRTX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 10.93% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.53% during the next five years compared to 11.42% growth over the previous five years of trading.
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Trading Performance Indicators
Check out the current performance indicators for Vertex Pharmaceuticals, Inc. (VRTX). In the past quarter, the stock posted a quick ratio of 3.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.02. Likewise, its price to free cash flow for the trailing twelve months is 32.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 15.41, a number that is poised to hit 4.16 in the next quarter and is forecasted to reach 18.15 in one year’s time.
Technical Analysis of Vertex Pharmaceuticals, Inc. (VRTX)
Looking closely at Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX), its last 5-days average volume was 1.45 million, which is a jump from its year-to-date volume of 1.24 million. As of the previous 9 days, the stock’s Stochastic %D was 38.76%. Additionally, its Average True Range was 9.14.
During the past 100 days, Vertex Pharmaceuticals, Inc.’s (VRTX) raw stochastic average was set at 86.75%, which indicates a significant increase from 50.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 13.45% in the past 14 days, which was lower than the 17.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $445.30, while its 200-day Moving Average is $406.09. However, in the short run, Vertex Pharmaceuticals, Inc.’s stock first resistance to watch stands at $478.67. Second resistance stands at $483.56. The third major resistance level sits at $489.19. If the price goes on to break the first support level at $468.15, it is likely to go to the next support level at $462.52. Now, if the price goes above the second support level, the third support stands at $457.63.
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Key Stats
There are currently 258,053K shares outstanding in the company with a market cap of 122.26 billion. Presently, the company’s annual sales total 9,869 M according to its annual income of 3,620 M. Last quarter, the company’s sales amounted to 2,691 M and its income totaled 1,100 M.
